Amgen sales rose by 5% in Q1

Share this article:

First-quarter Kyprolis sales of $68 million helped increase Amgen's first-quarter sales by 5% compared to the same period last year.

While the biotech saw increased demand and sales for drugs, including bone biologic Prolia and anemia product Epogen, demand and sales declined for some brands, with sales of RA shot Enbrel slipping 5% and kidney drug Aranesp sales falling 2% compared to the same period last year. The company attributed some of this fall-off to inventory draw-down.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters